Ibritumomab Tiuxetan: uses, dosing, side effects & brands
Ibritumomab Tiuxetan is a medicine sold in the U.S. under one brand, for follicular lymphoma, non-hodgkin lymphoma and b-cell lymphoma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Follicular Lymphoma, Non-Hodgkin Lymphoma and B-Cell Lymphoma
- Available as
- Kit
- Sold as
- Zevalin
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Boxed warning
- Boxed warning
How ibritumomab tiuxetan is dosed
From the FDA label for Zevalin (application BLA125019). Other ibritumomab tiuxetan products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Day 1 : Administer rituximab 250 mg/m 2 intravenous infusion. ( 2.2 ) Day 7, 8, or 9 : Administer rituximab 250 mg/m 2 intravenous infusion. ( 2.2 ) If platelets at least 150,000/mm 3 : Within 4 hours after rituximab infusion, administer 0.4 mCi/kg (14.8 MBq per kg) Y-90 Zevalin intravenous infusion. If platelets 100,000 to 149,000/mm 3 in relapsed or refractory patients: Within 4 hours after rituximab infusion, administer 0.3 mCi/kg (11.1 MBq per kg) Y-90 Zevalin intravenous infusion. 2.1 Recommended Dosing Schedule Administer the Zevalin therapeutic regimen as outlined below. Initiate the Zevalin therapeutic regimen following recovery of platelet counts to 150,000/mm 3 or more at least 6 weeks, but no more than 12 weeks, following the last dose of first-line chemotherapy. Only administer rituximab/Zevalin in facilities where immediate access to resuscitative measures is available. Overview of Dosing Schedule Zevalin Dosing Schedule 2.2 Zevalin Therapeutic Regimen Dosage and Administration Day 1: Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally prior to rituximab infusion. Administer rituximab 250 mg/m 2 intravenously at an initial rate of 50 mg/hr. In the absence of infusion reactions, escalate the infusion rate in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. Do not mix or dilute rituximab with other drugs. Immediately stop the…
Ibritumomab Tiuxetan side effects
The following serious adverse reactions are discussed in greater detail in other sections of the label: Serious Infusion Reactions [ see Boxed Warning and Warnings and Precautions ( 5.1 ) ] . Prolonged and Severe Cytopenias [ see Boxed Warning and Warnings and Precautions ( 5.2 ) ]. Severe Cutaneous and Mucocutaneous Reactions [ see Boxed Warning and Warnings and Precautions ( 5.3 ) ]. Leukemia and Myelodysplastic Syndrome [ see Warnings and Precautions ( 5.4 ) ]. Common adverse reactions ( > 10%) in clinical trials were: cytopenias, fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, and pyrexia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Acrotech Biopharma Inc. at 1-866-298-8433 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The reported safety data reflects exposure to Zevalin in 349 patients with relapsed or refractory, low-grade, follicular or transformed NHL across 5 trials (4 single arm and 1 randomized) and in 206 patients with previously untreated follicular NHL in a randomized trial (FIT study) who received any portion of the Zevalin…
Who shouldn’t take ibritumomab tiuxetan
None. None.
Ibritumomab Tiuxetan drug interactions
Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia. No formal drug interaction studies have been performed with Zevalin. Monitor patients receiving medications that interfere with platelet function or coagulation more frequently for thrombocytopenia. ( 7 )
Every ibritumomab tiuxetan product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Zevalin.
What people report to the FDA about ibritumomab tiuxetan
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 283 reports naming ibritumomab tiuxetan, and the FDA flagged 98% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- myelodysplastic syndrome56 reports
- febrile neutropenia42 reports
- thrombocytopenia40 reports
- neutropenia37 reports
- acute myeloid leukaemia30 reports
- anaemia26 reports
- pneumonia26 reports
- infection18 reports
Read these as a signal, not a rate. A report does not mean ibritumomab tiuxetan caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is ibritumomab tiuxetan?
Zevalin (Ibritumomab Tiuxetan) is a medication used to treat Follicular Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma.
Can you take ibritumomab tiuxetan with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run ibritumomab tiuxetan against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does ibritumomab tiuxetan come in?
Across the brands we track, ibritumomab tiuxetan is currently marketed as kit, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic ibritumomab tiuxetan?
We do not currently list a generic-labelled ibritumomab tiuxetan product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Ibritumomab Tiuxetan: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/ibritumomab-tiuxetan
- MLA
- “Ibritumomab Tiuxetan: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/ibritumomab-tiuxetan.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for ibritumomab tiuxetan on DailyMed (NIH) ↗ — including its boxed warning in full.